Ayala Pharmaceuticals Email Format

Pharmaceutical ManufacturingDelaware, United States11-50 Employees

Ayala Pharmaceuticals, Inc. operates as a clinical-stage oncology company focused on developing small-molecule therapies for people with rare tumors and aggressive cancers, while also pursuing Lm-based antigen delivery products for more common cancers. Its core pipeline includes AL102, an oral gamma secretase inhibitor for desmoid tumors, and AL101, an intravenous gamma secretase inhibitor for adenoid cystic carcinoma, along with ADXS-504, an Lm-based immunotherapy for early-stage prostate cancer. AL102 has received Fast Track designation from the U.S. FDA and is in the Phase 3 segment of a pivotal study for desmoid tumors. The firm is based in Wilmington, Delaware, and operates with a relatively small team. In 2023, Ayala completed a merger with Biosight, consolidating its oncology development activities. In early 2024, the company announced an agreement to divest its AL101 and AL102 programs to Immunome.

Sign up for free to view info

Company overview Employee directory